Search
Firocoxib
go.drugbank.com/drugs/DB09217ExperimentalVet approvedIt currently approved for veterinary use in dogs and horses under the brand names Equioxx and Previcox. Firocoxib was the first COX-2 inhibitor approved by the U.S.
Encorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalFDA-approved test. … approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an
Simeprevir
go.drugbank.com/drugs/DB06290ApprovedWithdrawnSimeprevir was approved by the FDA in November 2014 and is marketed under the brand name Olysio as oral tablets. … Sustained virologic response 12 weeks after planned end of treatment (SVR12) was achieved in 170/176 (97%) subjects without cirrhosis treated with 12 weeks simeprevir in combination with sofosbuvir (FDA
Dimethylthiambutene
go.drugbank.com/drugs/DB01444ExperimentalIllicitDimethylthiambutene (N,N-Dimethyl-1-methyl-3,3-di-2-thienylallylamine, Dimethibutin, Ohton) is an opioid analgesic drug. … It is now under international control under Schedule I of the UN Single Convention On Narcotic Drugs 1961, presumably due to high abuse potential, although little more information is available.
Synonyms: 3-dimethylamino-1,1-di-(2'-thienyl)-1-butene, N,N,1-trimethyl-3,3-di-2-thienylallylamineFluciclovine (18F)
go.drugbank.com/drugs/DB13146ApprovedInvestigational[A31385] Fluciclovine was developed by Blue Earth Diagnostics, Ltd. and FDA approved in May 27, 2016.[L1049]
Cysteamine
go.drugbank.com/drugs/DB00847ApprovedInvestigational[L15611] On August 25th 2020, the first ophthalmic solution for cystinosis requiring only 4 daily treatments was granted FDA approval. … [L15606,L15616] In particular, cystine deposits on the eye can cause significant discomfort throughout the day and require frequent treatment with eye drops, typically every waking hour.
Etidronic acid
go.drugbank.com/drugs/DB01077ApprovedInvestigational[A203111] Etidronic acid was granted FDA approval on 1 September 1977.[L13901]
Doxorubicin
go.drugbank.com/drugs/DB00997ApprovedInvestigational[A257614] Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin
Products: DOXOLEM RU, DOXORUBICIN AU 2MG/ML 10MGTarlatamab
go.drugbank.com/drugs/DB17256ApprovedInvestigational[L50743] Tarlatamab-dlle was approved by the FDA in May 2024 for use in patients who have failed previous round of platinum-based chemotherapy,[L50743,L50748] becoming the first DLL3-targeting bispecific … [L50748] It is a bispecific monoclonal antibody that targets CD3 expressed on the surface of T-cells and delta-like ligand 3 (DLL3), an inhibitory ligand that suppresses Notch signaling and is highly expressed